^
Association details:
| Biomarker: | EHD1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | erlotinib (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
NF-?B-driven improvement of EHD1 contributes to erlotinib resistance in EGFR-mutant lung cancers
Published date:
04/01/2018
Excerpt:
To elucidate the relationship between EHD1 expression and EGFR-TKI resistance, we retrospectively evaluated specimens from a total of 24 lung cancer patients who had received EGFR-TKIs (erlotinib or gefitinib)….As shown in Fig. 1b, EHD1 overexpression was more frequently observed in patients with a poor response to EGFR-TKIs therapy than in patients who responded to EGFR-TKI treatment.
DOI:
10.1038/s41419-018-0447-7